UK
Practice Areas
Intellectual Property
Patents
Life Sciences and Healthcare
Pharmaceuticals and Biotechnology
Career
Please see https://www.hoganlovells.com/en/daniel-brook for further information.
Professional Memberships
AIPPI Council Member
CIPA
EPLAW
Experience
Daniel is a patent litigator in the UK. He acts for clients such as MSD, Lilly, Amgen and BMS. Recent key cases include Actavis v Lilly (Supreme Court), Schutz v Werit (Supreme Court), and BMS v Teva (availability of interim injunctions).
He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.
Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars, IAM Patent 1000 and Who's Who Legal.
Work Highlights
- Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.
- Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed (Supreme Court) and gemcitabine.
- Acting for BMS in relation to patent challenges around its products, dasatinib, efavirenz and atazanavir.
- Acting for a number of electronic clients including HTC, ZTE and BlackBerry on European patent litigation matters.
